Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 2/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 12/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952668 | 0.87 | CHEK1 (0.69) | MAP2K4CHEK1CHEK2CDK1KDR | |
| SCHEMBL5952883 | 0.86 | MAP2K4 (0.60) | MAP2K4CHEK1CHEK2CDK1KDR | |
| SCHEMBL3535642 | 0.84 | CHEK1 (0.80) | CHEK1CDK1KDRITK | |
| SCHEMBL31172388 | 0.84 | CHEK1 (0.58) | MAP2K4CHEK1CHEK2ITK | |
| SCHEMBL5248306 | 0.82 | CHEK1 (0.86) | CHEK1CDK1KDR | |
| SCHEMBL5951932 | 0.82 | CHEK1 (0.69) | MAP2K4CHEK1CDK1KDRITK | |
| SCHEMBL4919171 | 0.82 | FGFR1 (0.64) | MAP2K4CHEK1CHEK2CDK1KDR | |
| SCHEMBL5951619 | 0.80 | CDK4 (0.55) | CHEK1CHEK2KDR | |
| SCHEMBL31172403 | 0.79 | CHEK1 (0.70) | MAP2K4CHEK1CHEK2CDK1KDR | |
| SCHEMBL144764 | 0.78 | MAP2K4 (0.65) | MAP2K4CHEK1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | MAP2K4 252/4885CHEK1 286/4885CHEK2 239/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | MAP2K4 376/4885CHEK1 321/4885CHEK2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.